DBV Technologies (DBVT NASDAQ) stock market data APIs
$14.1486
0.03(0.2%)
as of August 11, 2026
Try our APIs with
free plan!
DBV Technologies Financial Data Overview
Price chart is built with
Anychart
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Prev. Close
14.1486
Open
14.1778
High
14.3457
Low
14.0639
52 wk Range
8.7-26.185
Market Cap
897 M
Shares Outstanding
62 846 K
Revenue
5 036 K
EPS
-0.6
Beta
-0.236
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get DBV Technologies data using free add-ons & libraries
Get DBV Technologies Fundamental Data
DBV Technologies Fundamental data includes:
- Net Revenue: 5 036 K
- EBITDA: -174 762 000
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-07-16
- EPS/Forecast: -0.12
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
DBV Technologies News
New
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0...
European Equities Traded in US as ADRs Ease in Tuesday Trading
European equities traded in the US as American depositary receipts eased late Tuesday morning with t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight
The food allergy market landscape is advancing through a robust clinical pipeline, with key programs being developed by companies such as DBV Technologies (Viaskin [DBV712] Peanut Patch), Novartis (Re...
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking higher late Wednesd PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Get DBV Technologies fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
